Heart failure & cardiomyopathies
Aficamten in symptomatic obstructive hypertrophic cardiomyopathy: the FOREST-HCM long-term study
Authors' conclusion
Extended aficamten treatment in patients with symptomatic oHCM yielded early and sustained hemodynamic and clinical responses with low incidences of new-onset atrial fibrillation and LVEF<50%.
Study context
- Population
- Patients with symptomatic obstructive hypertrophic cardiomyopathy (HCM) completing a parent aficamten study352 patient-years exposure
- Participants
- 296 patients
- Outcome
- Change from baseline in Valsalva LV outflow tract gradient
- Follow-up
- Weeks 12 and 96
Methodological detailslong-term, Enrolled May 2021 to August 2024
- Long-term
- Enrolled May 2021 to August 2024
Main finding
As reported in the abstract
| Group | Value | Week 96 reduction |
|---|---|---|
| Aficamten | mean reduction 56 (SD 43) mmHg | 62 ± 33 mmHg |
Aficamten
Valuemean reduction 56 (SD 43) mmHg
Week 96 reduction62 ± 33 mmHg
- Both reductions vs baseline
- P < 0.0001
Further findings
| Outcome | Values |
|---|---|
| LVEF change from baseline · Weeks 12 and 96 | Aficamten −3% (SD 6%) · Week 96 −5% ± 5% |
| ≥1 NYHA class improvement · Weeks 12 and 96 | Aficamten 69% · Week 96 93% |
| KCCQ-Clinical Summary Score improvement · Weeks 12 and 96 | Aficamten 15 (SD 16) points · Week 96 16 ± 16 points |
Safety
Treatment-emergent serious adverse events (TESAEs)
- Patients with TESAEs
- 36 (12.2%)
- Deaths, HF or events considered related to aficamten
- 0
- Terminated therapy due to a TESAE (ischemic colitis)
- 1 (0.3%)
Left ventricular ejection fraction (LVEF)<50%
- Patients with LVEF<50%
- 10 (3.4%)
- Exposure-adjusted incidence rate (EAIR)
- 2.9 per 100 patient-years
- With non-serious mild/moderate dyspnoea
- 2
- Treatment interruptions for LVEF<50%
- 0
- Events of LVEF<40%
- 0
New-onset AF
- Patients with new-onset AF
- 7 (2.4%)
- EAIR
- 2.0 per 100 patient-years
Original publication
Aficamten in symptomatic obstructive hypertrophic cardiomyopathy: the FOREST-HCM long-term study. Eur Heart J. Published 5 March 2026. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →